McDaniel Larry S, Swiatlo Edwin
Department of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Southeast Louisiana Veterans Health Care Network, New Orleans, Louisiana, USA.
Open Forum Infect Dis. 2021 Dec 18;8(12):ofab576. doi: 10.1093/ofid/ofab576. eCollection 2021 Dec.
The sudden emergence and global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have greatly accelerated the adoption of novel vaccine strategies, which otherwise would have likely languished for years. In this light, vaccines for certain other pathogens could certainly benefit from reconsideration. One such pathogen is (pneumococcus), an encapsulated bacterium that can express >100 antigenically distinct serotypes. Current pneumococcal vaccines are based exclusively on capsular polysaccharide-either purified alone or conjugated to protein. Since the introduction of conjugate vaccines, the valence of pneumococcal vaccines has steadily increased, as has the associated complexity and cost of production. There are many pneumococcal proteins invariantly expressed across all serotypes, which have been shown to induce robust immune responses in animal models. These proteins could be readily produced using recombinant DNA technology or by mRNA technology currently used in SARS-CoV-2 vaccines. A door may be opening to new opportunities in affordable and broadly protective vaccines.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的突然出现和全球传播极大地加速了新型疫苗策略的采用，否则这些策略可能会停滞数年。有鉴于此，某些其他病原体的疫苗肯定会受益于重新审视。这样一种病原体就是肺炎链球菌，一种可表达100多种抗原性不同血清型的包膜细菌。目前的肺炎球菌疫苗完全基于荚膜多糖——单独纯化或与蛋白质结合。自结合疫苗推出以来，肺炎球菌疫苗的价数稳步增加，生产的相关复杂性和成本也随之增加。在所有血清型中都有许多恒定表达的肺炎球菌蛋白，这些蛋白已被证明能在动物模型中诱导强烈的免疫反应。这些蛋白可以很容易地通过重组DNA技术或目前用于SARS-CoV-2疫苗的mRNA技术来生产。一扇通往价格合理且具有广泛保护作用疫苗的新机遇之门可能正在打开。
